A number of analysts have recently commented on LIVN shares. Piper Jaffray Companies set a $90.00 target price on LivaNova and gave the stock a “buy” rating in a research note on Friday, September 6th. BidaskClub cut LivaNova from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. downgraded LivaNova from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Berenberg Bank restated a “buy” rating and issued a $114.00 price objective on shares of LivaNova in a research report on Monday, September 9th. Finally, upgraded LivaNova from a “hold” rating to a “buy” rating in a research report on Thursday, November 7th.
In related news, Director Daniel Jeffrey Moore sold 3,000 shares of the company’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $80.00, for a total value of $240,000.00. Following the completion of the transaction, the director now owns 28,352 shares of the company’s stock, valued at approximately $2,268,160. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Damien Mcdonald sold 1,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $83.71, for a total value of $83,710.00. Following the completion of the transaction, the chief executive officer now directly owns 66,016 shares of the company’s stock, valued at approximately $5,526,199.36. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,000 shares of company stock worth $471,230. Corporate insiders own 0.41% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD grew its stake in LivaNova by 18.8% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,395,068 shares of the company’s stock valued at $172,349,000 after acquiring an additional 378,564 shares during the period. Invesco Ltd. lifted its holdings in LivaNova by 376.8% during the second quarter. Invesco Ltd. now owns 2,299,007 shares of the company’s stock valued at $165,437,000 after purchasing an additional 1,816,788 shares in the last quarter. UBS Asset Management Americas Inc. grew its position in shares of LivaNova by 22.9% in the second quarter. UBS Asset Management Americas Inc. now owns 1,390,299 shares of the company’s stock valued at $100,046,000 after purchasing an additional 259,369 shares during the period. Wells Fargo & Company MN grew its position in shares of LivaNova by 11.5% in the second quarter. Wells Fargo & Company MN now owns 1,322,072 shares of the company’s stock valued at $95,136,000 after purchasing an additional 136,777 shares during the period. Finally, Northern Trust Corp increased its stake in shares of LivaNova by 0.6% during the second quarter. Northern Trust Corp now owns 778,763 shares of the company’s stock worth $56,040,000 after purchasing an additional 4,317 shares in the last quarter. 87.80% of the stock is currently owned by institutional investors.
NASDAQ LIVN opened at $75.06 on Friday. LivaNova has a 1 year low of $64.80 and a 1 year high of $102.43. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.17 and a quick ratio of 0.81. The company has a market capitalization of $3.65 billion, a PE ratio of 23.68, a P/E/G ratio of 3.44 and a beta of 0.59. The company has a fifty day moving average of $78.15 and a 200 day moving average of $76.02.
LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $0.84 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.09. The company had revenue of $268.60 million for the quarter, compared to the consensus estimate of $273.41 million. LivaNova had a positive return on equity of 9.44% and a negative net margin of 20.35%. The firm’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period last year, the firm earned $0.78 EPS. Research analysts expect that LivaNova will post 2.69 earnings per share for the current year.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Featured Story: Buy Rating
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with .